Responses
Original research
Direct delivery of an investigational cell therapy in patients with Parkinson’s disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design
Compose a Response to This Article
Other responses
No responses have been published for this article.